Literature DB >> 17508196

Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer.

M Chattopadhyay1, M Mata, J Goss, D Wolfe, S Huang, J C Glorioso, D J Fink.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to determine whether prolonged expression of neurotrophin-3 (NT-3) in mice, achieved by herpes simplex virus (HSV)-mediated gene transfer with gene expression under the control of an HSV latency promoter, can provide protection against the progression of diabetic neuropathy over a 6 month period.
MATERIALS AND METHODS: Mice with diabetes induced by streptozotocin were inoculated s.c. into both hind feet with a non-replicating HSV vector containing the coding sequence for NT-3 under the control of the HSV latency-associated promoter 2 (LAP2) elements or with a control vector. Nerve function was evaluated by electrophysiological and behavioural measures over the course of 6 months after the onset of diabetes.
RESULTS: Animals inoculated with the NT-3-expressing vector, but not animals inoculated with control vector, showed preservation of sensory and motor nerve amplitude and conduction velocity measured electrophysiologically, small fibre sensory function assessed by withdrawal from heat, autonomic function measured by pilocarpine-induced sweating, skin innervation assessed by protein gene product 9.5 staining of axons, and density of calcitonin gene-related peptide terminals in the spinal cord measured by immunohistochemistry 5.5 months after vector inoculation. CONCLUSIONS/
INTERPRETATION: These results indicate that the continuous production of NT-3 by LAP2-driven expression of the transgene from an HSV vector over a 6 month period protects against progression of diabetic neuropathy in mice, and provide a proof-of-principle demonstration for the development of a novel therapy for preventing the progression of diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508196     DOI: 10.1007/s00125-007-0702-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

Review 1.  Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches.

Authors:  Hans Thoenen; Michael Sendtner
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

2.  Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy.

Authors:  Munmun Chattopadhyay; James Goss; Darren Wolfe; William C Goins; Shaohua Huang; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Brain       Date:  2004-01-28       Impact factor: 13.501

3.  Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats.

Authors:  A P Mizisin; N A Calcutt; D R Tomlinson; A Gallagher; P Fernyhough
Journal:  J Peripher Nerv Syst       Date:  1999       Impact factor: 3.494

Review 4.  Trophic interactions between sensory nerves and their targets.

Authors:  W P Chen; Y C Chang; S T Hsieh
Journal:  J Biomed Sci       Date:  1999 Mar-Apr       Impact factor: 8.410

5.  HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy.

Authors:  W M Walwyn; Y Matsuka; D Arai; D C Bloom; H Lam; C Tran; I Spigelman; N T Maidment
Journal:  Exp Neurol       Date:  2006-01-20       Impact factor: 5.330

6.  Cutaneous overexpression of NT-3 increases sensory and sympathetic neuron number and enhances touch dome and hair follicle innervation.

Authors:  K M Albers; T N Perrone; T P Goodness; M E Jones; M A Green; B M Davis
Journal:  J Cell Biol       Date:  1996-07       Impact factor: 10.539

7.  Neurotrophin-3 is increased in skin in human diabetic neuropathy.

Authors:  A J Kennedy; A Wellmer; P Facer; G Saldanha; P Kopelman; R M Lindsay; P Anand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

8.  Nerve growth factor administration protects against experimental diabetic sensory neuropathy.

Authors:  S C Apfel; J C Arezzo; M Brownlee; H Federoff; J A Kessler
Journal:  Brain Res       Date:  1994-01-14       Impact factor: 3.252

9.  A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats.

Authors:  W F Goins; L R Sternberg; K D Croen; P R Krause; R L Hendricks; D J Fink; S E Straus; M Levine; J C Glorioso
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

Review 10.  Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?

Authors:  Stuart C Apfel
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

View more
  19 in total

1.  Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin.

Authors:  Zetang Wu; Marina Mata; David J Fink
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

3.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 4.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

Review 5.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

6.  Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element.

Authors:  Z Wu; M Mata; D J Fink
Journal:  Gene Ther       Date:  2011-11-17       Impact factor: 5.250

Review 7.  Gene therapy for the treatment of diabetic neuropathy.

Authors:  Marina Mata; Munmun Chattopadhyay; David J Fink
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

Review 8.  Epidermal nerve fiber quantification in the assessment of diabetic neuropathy.

Authors:  Kristina K Beiswenger; Nigel A Calcutt; Andrew P Mizisin
Journal:  Acta Histochem       Date:  2008-04-01       Impact factor: 2.479

Review 9.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  HSV-mediated gene transfer of C3 transferase inhibits Rho to promote axonal regeneration.

Authors:  Zhigang Zhou; Xiangmin Peng; Peipei Chiang; Jeeyong Kim; Xiankui Sun; David J Fink; Marina Mata
Journal:  Exp Neurol       Date:  2012-06-26       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.